In 2007, Mylan secured rights to the nearly fifty year old EpiPen, used to treat anaphylaxis (severe allergic reactions).[29] Bresch advocated for broader availability of EpiPens in public places and helped pass the School Access to Emergency Epinephrine Act which made epinephrine more accessible in schools.[17][30] Between 2009 and May 2016, under Bresch's tenure as Mylan president, Mylan raised the price of a set of pens by nearly 500 %, from $103.50 to $608.61.[29] Proxy filings show that from 2007 to 2015, Bresch's compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, EpiPen prices went from $56.64 to $317.82, a 461 percent increase, according to data provided by Connecture.[31]